<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4798055</article-id><article-id pub-id-type="publisher-id">555</article-id><article-id pub-id-type="doi">10.1186/2197-425X-3-S1-A411</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Long-term effects of remote ischaemic preconditioning in high risk patients undergoing cardiac surgery: follow-up of a randomised clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Zarbock</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kellum</surname><given-names>J</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Van Aken</surname><given-names>H</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>C</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Martens</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>G&#x000f6;rlich</surname><given-names>D</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Meersch</surname><given-names>M</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>University Hospital M&#x000fc;nster, M&#x000fc;nster, Germany </aff><aff id="Aff2"><label/>University of Pittsburgh, Pittsburgh, PA USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 1</issue><issue-sponsor>The publication charges for this supplement were funded by Intensive Care Medicine Experimental.</issue-sponsor><elocation-id>A411</elocation-id><permissions><copyright-statement>&#x000a9; Zarbock et al.; 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><conference><conf-name>ESICM LIVES 2015</conf-name><conf-loc>Berlin, Germany</conf-loc><conf-date>3-7 October 2015</conf-date><string-conf><uri>http://www.esicm.org/</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Acute kidney injury (AKI) is a common complication after cardiac surgical procedures and is associated with an increased morbidity and mortality.</p></sec><sec id="Sec2"><title>Objective</title><p>In a multicenter randomized trial, we found that remote ischemic preconditioning (RIPC) reduced acute kidney injury (AKI) in high risk patients undergoing cardiac surgery. We now report on the effects of RIPC on long-term outcomes.</p></sec><sec id="Sec3"><title>Methods</title><p>In this follow up of the RenalRIPC trial, we examined the effect of RIPC the composite end-point of all-cause mortality, need for renal replacement therapy, and persistent renal dysfunction at 90 days (MAKE<sub>90</sub>). Secondary outcomes were renal recovery and dialysis dependence in patients with AKI.</p></sec><sec id="Sec4"><title>Results</title><p>RIPC significantly reduced the occurrence of MAKE<sub>90</sub> (17/120 (14.2%)) compared to the sham group (30/120 (25.0%); ARR, 10.8%, 95% CI 0.9%-20.8%, P = 0.034). In the 108/240 patients who developed post-surgery AKI (RIPC 45 (37.5%), Sham-RIPC 63 (52.5%)), 2 (5.3%) in the RIPC group and 11 (22.0%) in the Sham-RIPC did not recovery renal function by 90-days; ARR 16.7%, 95% CI, 3.2%-30.2%, P = 0.028) and 1 (2.4%) versus 8 (15.4%) were dialysis dependent; ARR 13.0%, 95% CI, 2.1%-23.8%, P = 0.036). A receiver operating characteristic (ROC) curve analysis for the MAKE<sub>90</sub> showed best performance for insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) ([TIMP-2]&#x000b7;[IGFBP7]) at 4 h (AUC 0.64; 95% CI 0.547-0.736, P = 0.004). The ROC analyses including AKI positive patients showed that [TIMP-2]&#x000b7;[IGFBP7] was predictive at 4h for renal non-recovery (AUC 0.70; 95% CI, 0.587-0.818; P = 0.021) and at 12 h (AUC 0.74; 95% CI, 0.604-0.879; P = 0.006) after cardiopulmonary bypass. The maximum urinary [TIMP-2]&#x000b7;[IGFBP7] demonstrated an AUC of 0.75 (95% CI, 0.640-0.865; P = 0.004). Optimal cut points were determined from the ROC analyses maximizing the Youden Index ([TIMP-2]&#x000b7;[IGFBP7] at 4h = 0.7; [TIMP-2]&#x000b7;[IGFBP7] at 12h = 0.67, [TIMP-2]&#x000b7;[IGFBP7] maximum = 0.86). Sensitivities ranged from 0.50 to 0.55, specificities from 0.75 to 0.82.</p></sec><sec id="Sec5"><title>Conclusions</title><p>RIPC significantly reduced the 3-month incidence of a composite end point of all-cause mortality, need for renal replacement therapy, and persistent renal dysfunction in high risk patients undergoing cardiac surgery. Furthermore, RIPC enhanced renal recovery in patients with AKI.</p></sec><sec id="Sec6"><title>Trial Registration</title><p>The trial is registered at <ext-link ext-link-type="uri" xlink:href="http://www.drks.de">http://www.drks.de</ext-link> (Identifier: DRKS00005333).</p></sec></body></article>